Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRO-CKD balcinrenone plus dapagliflozin dose-finding study in chronic kidney disease with albuminuria
jRCT2031240054Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of balcinrenone and dapagliflozin in chronic kidney disease (CKD) and albuminuria (3 arms), sponsored by AstraZeneca. Primary endpoint: Relative change in urine albumin-to-creatinine ratio from baseline to Week 12. Started Jul 2024; status: completed.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)albuminuria
Beyond the preview
Go deeper on jRCT2031240054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240054.